News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
489,785 Results
Type
Article (8653)
Company Profile (147)
Press Release (480984)
Multimedia
Podcasts (6)
Webinars (8)
Section
Business (168533)
Career Advice (319)
Deals (25936)
Drug Delivery (9)
Drug Development (53727)
Employer Resources (15)
FDA (9905)
Job Trends (8692)
News (240810)
Policy (18080)
Tag
2027 Bio NC Standard (2)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (4)
2027 Genetown Elite (1)
2027 Genetown Standard (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (510)
Accelerated approval (26)
ADA (19)
Adcomms (6)
Allergies (102)
Alliances (33541)
ALS (106)
Alzheimer's disease (988)
Antibody-drug conjugate (ADC) (285)
Approvals (10501)
Artificial intelligence (329)
ASCO (163)
Autoimmune disease (209)
Automation (28)
Bankruptcy (263)
Best Places to Work (7037)
BIO (37)
Biologics (2)
BIOSECURE Act (5)
Biosimilars (111)
BioSpace Insights (17)
Biotechnology (95)
Bladder cancer (138)
Brain cancer (30)
Breast cancer (512)
Cancer (3734)
Cardiovascular disease (227)
Career advice (254)
Career pathing (1)
CAR-T (184)
CDC (1)
Celiac Disease (1)
Cell therapy (512)
Cervical cancer (34)
Clinical research (48565)
Collaboration (1286)
Commercialization (3)
Compensation (1470)
Complete response letters (37)
COVID-19 (826)
CRISPR (69)
C-suite (785)
Cystic fibrosis (86)
Data (5757)
Denatured (4)
Depression (102)
Dermatology (62)
Diabetes (351)
Diagnostics (4219)
Digital health (40)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (160)
Drug pricing (8)
Drug shortages (2)
Duchenne muscular dystrophy (165)
Earnings (73948)
Editorial (4)
Employer branding (2)
Employer resources (15)
Events (88379)
Executive appointments (726)
FDA (12573)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (18)
Frontotemporal dementia (23)
Funding (968)
Gene editing (134)
Generative AI (9)
Gene therapy (351)
GLP-1 (304)
Government (976)
Grass and pollen (2)
Guidances (284)
Healthcare (9526)
Hematology (97)
HIV (52)
Huntington's disease (22)
IgA nephropathy (64)
Immunology and inflammation (109)
Immuno-oncology (57)
Indications (159)
Infectious disease (1016)
Inflammatory bowel disease (135)
Inflation Reduction Act (4)
Influenza (84)
Intellectual property (256)
Interviews (43)
IPO (12483)
IRA (2)
Job creations (2005)
Job search strategy (244)
JPM (3)
Kidney cancer (16)
Labor market (5)
Layoffs (74)
Legal (5214)
Licensing (8)
Liver cancer (45)
Longevity (18)
Lung cancer (526)
Lymphoma (255)
Machine learning (27)
Management (4)
Manufacturing (546)
Marketing (9)
MASH (120)
Medical device (8715)
Medtech (8861)
Mergers & acquisitions (14500)
Metabolic disorders (721)
mRNA (62)
Multiple sclerosis (102)
NASH (4)
Neurodegenerative disease (230)
Neuropsychiatric disorders (39)
Neuroscience (1857)
NextGen: Class of 2026 (3211)
Non-profit (876)
Now hiring (4)
Obesity (228)
Opinion (13)
Ovarian cancer (161)
Pain (182)
Pancreatic cancer (198)
Parkinson's disease (205)
Partnered (12)
Patents (477)
Patient recruitment (515)
Peanut (31)
People (42234)
Pharmaceutical (30)
Pharmacy benefit managers (8)
Phase 1 (15798)
Phase 2 (21731)
Phase 3 (14627)
Pipeline (7430)
Policy (30)
Postmarket research (1586)
Preclinical (6631)
Press Release (36)
Prostate cancer (192)
Psychedelics (8)
Radiopharmaceuticals (191)
Rare diseases (599)
Real estate (3076)
Recruiting (6)
Regulatory (15028)
Reports (23)
Research institute (612)
Resumes & cover letters (48)
Rett syndrome (42)
RNA editing (5)
RSV (48)
Schizophrenia (102)
Series A (174)
Series B (125)
Service/supplier (5)
Sickle cell disease (64)
Special edition (2)
Spinal muscular atrophy (90)
Sponsored (6)
Startups (2080)
Stomach cancer (3)
Supply chain (51)
Tariffs (2)
The Weekly (2)
Vaccines (342)
Venture capital (20)
Weight loss (75)
Women's health (81)
Date
Today (53)
Last 7 days (216)
Last 30 days (1609)
Last 365 days (19348)
2026 (12532)
2025 (19636)
2024 (23340)
2023 (26983)
2022 (35112)
2021 (37681)
2020 (33871)
2019 (23669)
2018 (17729)
2017 (19020)
2016 (18188)
2015 (24499)
2014 (21835)
2013 (18271)
2012 (20318)
2011 (20581)
2010 (20427)
Location
Africa (237)
Alabama (73)
Alaska (2)
Arizona (305)
Arkansas (11)
Asia (18525)
Australia (2158)
California (12103)
Canada (3188)
China (564)
Colorado (487)
Connecticut (411)
Delaware (219)
Europe (25852)
Florida (1809)
Georgia (383)
Hawaii (3)
Idaho (46)
Illinois (701)
India (51)
Indiana (314)
Iowa (15)
Japan (418)
Kansas (101)
Kentucky (31)
Louisiana (27)
Maine (26)
Maryland (1222)
Massachusetts (8005)
Michigan (309)
Minnesota (565)
Mississippi (4)
Missouri (82)
Montana (20)
Nebraska (11)
Nevada (118)
New Hampshire (61)
New Jersey (2636)
New Mexico (14)
New York (2842)
North Carolina (1287)
North Dakota (4)
Northern California (6053)
Ohio (279)
Oklahoma (14)
Oregon (16)
Pennsylvania (2310)
Puerto Rico (20)
Rhode Island (30)
South America (464)
South Carolina (76)
South Dakota (1)
Southern California (5018)
Tennessee (121)
Texas (1968)
United States (39352)
Utah (361)
Vermont (1)
Virginia (154)
Washington D.C. (39)
Washington State (934)
West Virginia (1)
Wisconsin (73)
Wyoming (1)
489,785 Results for "sab biotherapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142
April 29, 2026
·
4 min read
Press Releases
SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights
August 6, 2026
·
11 min read
Press Releases
SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting
May 29, 2026
·
5 min read
Press Releases
SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET
July 30, 2026
·
1 min read
Diabetes
Type 1 diabetes pipeline making ‘remarkable progress’ toward insulin independence
After the trailblazing approval of Sanofi’s Tzield for stage 3 type 1 diabetes, several companies, including SAB Biotherapeutics and Eledon Pharmaceuticals, are vying for a spot in the landscape with innovative approaches—and experts say there’s room for all of them.
July 20, 2026
·
7 min read
·
Michael Gibney
Press Releases
SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress
April 15, 2026
·
6 min read
SAb Biotherapeutics Rebrands as SAB BIO
SAB Biotherapeutics today announced its new name, SAB BIO, and visual identity to more closely align with its mission to treat and prevent immune and autoimmune disorders with the use of its unique immunotherapy platform.
June 20, 2024
·
5 min read
SAB Biotherapeutics Provides SAB-142 Trial Update
SAB Biotherapeutics, Inc. today announced their Chief Medical Officer, Dr. Alexandra Kropotova, MD, MBA disclosed that SAB has completed dosing the third cohort for SAB-142.
April 16, 2024
·
5 min read
Press Releases
Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes
July 7, 2026
·
6 min read
Press Releases
SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights
May 12, 2026
·
9 min read
1 of 48,979
Next
